Cancer Gene Therapy Market Size, Share, Trends, Key Drivers, Demand and Opportunity Analysis

Global Cancer Gene Therapy Market – Industry Trends and Forecast to 2029

Global Cancer Gene Therapy Market, By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), End User (Hospitals, Oncology Institutes, Biotechnological Companies, Clinical Research Laboratories) – Industry Trends and Forecast to 2029.

Data Bridge Market Research analyses that the cancer gene therapy market which was USD 1.73 billion in 2021, would rocket up to USD 3.63 billion by 2029, and is expected to undergo a CAGR of 9.70% during the forecast period 2022 to 2029. 

Access Full 350 Pages PDF Report @

https://www.databridgemarketresearch.com/reports/global-cancer-gene-therapy-market

**Segments**

- **Therapy Type**: The cancer gene therapy market can be segmented by therapy type into gene induced immunotherapy, oncolytic virotherapy, gene transfer, and others. Gene-induced immunotherapy involves modifying the patient's immune cells to recognize and attack cancer cells, while oncolytic virotherapy uses viruses to infect and kill cancer cells. Gene transfer aims to replace or repair faulty genes within cancer cells as a treatment approach.

- **Application**: In terms of application, the market can be segmented into prostate cancer, breast cancer, lung cancer, leukemia, and others. Different types of cancer may require specific gene therapy approaches tailored to the genetic mutations and characteristics of the cancer cells involved.

- **End User**: The cancer gene therapy market can also be segmented by end user, including hospitals, cancer research centers, and specialty clinics. These institutions play a crucial role in the development and administration of gene therapy treatments for cancer patients.

**Market Players**

- **Novartis AG**: Novartis is a leading player in the cancer gene therapy market, with a strong portfolio of gene therapy products and ongoing research and development efforts to advance the field.

- **Kite Pharma**: Acquired by Gilead Sciences, Kite Pharma is known for its CAR-T cell therapy products for treating certain types of blood cancers, making it a key player in the gene therapy market.

- **Spark Therapeutics**: Known for its gene therapy products targeting inherited retinal diseases, Spark Therapeutics has been at the forefront of gene therapy innovation and commercialization.

- **bluebird bio**: With a focus on developing gene therapies for severe genetic diseases and cancer, bluebird bio has established itself as a prominent player in the gene therapy market.

- **Adaptimmune Therapeutics**: Specializing in engineered T-cell therapies for cancer, Adaptimmune Therapeutics is actively involved in advancing gene therapy options for cancer patients.

The global cancer gene therapy market is dynamic and competitive, with key players driving innovationThe global cancer gene therapy market is witnessing significant growth and innovation driven by key market players leading the way in research, development, and commercialization of gene therapy products. Novartis AG stands out as a prominent player with a robust portfolio of gene therapy offerings aimed at revolutionizing cancer treatment. Their ongoing research efforts and strategic advancements are poised to make a substantial impact on the market. Additionally, the acquisition of Kite Pharma by Gilead Sciences has bolstered the presence of CAR-T cell therapy products in the market, particularly for blood cancer treatment, solidifying Kite Pharma as a key player in the gene therapy segment.

Spark Therapeutics has been pioneering gene therapy products for inherited retinal diseases, contributing significantly to the evolution of gene therapy and its application in treating genetic disorders. The company's innovative approaches and focus on commercialization have positioned it as a frontrunner in the market. bluebird bio's focus on developing gene therapies for severe genetic diseases and cancer has propelled its status as a notable player in the gene therapy sector. By leveraging cutting-edge technologies and strategic collaborations, bluebird bio continues to drive advancements in gene therapy for critical medical conditions.

Adaptimmune Therapeutics specializes in engineered T-cell therapies for cancer, offering promising solutions for cancer patients seeking advanced gene therapy options. Their dedication to advancing gene therapy applications in oncology underscores their commitment to addressing unmet medical needs in cancer treatment. These key market players play a pivotal role in shaping the landscape of the cancer gene therapy market, driving innovation, and expanding treatment options for patients worldwide.

The segmentation of the cancer gene therapy market based on therapy type, application, and end user provides a comprehensive framework for understanding the diverse needs and preferences within the market. With gene-induced immunotherapy, oncolytic virotherapy, gene transfer, and other therapeutic approaches, the market caters to a wide range of cancer types and treatment modalities. The application-based segmentation further highlights the specificity and customization required in gene therapy interventions for different types of cancer**Global Cancer Gene Therapy Market, By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), End User (Hospitals, Oncology Institutes, Biotechnological Companies, Clinical Research Laboratories) – Industry Trends and Forecast to 2029:**

The global cancer gene therapy market is set to witness substantial growth and innovation driven by key market players who are at the forefront of research, development, and commercialization of gene therapy products. Novartis AG, a prominent player in the market, possesses a robust portfolio of gene therapy offerings aimed at transforming cancer treatment. The company's ongoing research endeavors and strategic advancements are poised to have a significant impact on the market landscape. Additionally, the acquisition of Kite Pharma by Gilead Sciences has strengthened the prevalence of CAR-T cell therapy products in the market, particularly in the treatment of blood cancers, solidifying Kite Pharma's position as a key player in the gene therapy segment.

Spark Therapeutics has played a pioneering role in developing gene therapy products for inherited retinal diseases, making substantial contributions to the advancement of gene therapy and its application in treating genetic disorders. The company's innovative approaches and focus on commercialization have positioned it as a leader in the market. bluebird bio's dedication to developing gene therapies for severe genetic diseases and cancer has elevated its stature as a notable player in the gene therapy sector. Through the utilization of cutting-edge technologies and strategic partnerships, bluebird bio continues to lead the way in driving

 

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Key Questions Answered with this Study

1) What makes Cancer Gene Therapy Market feasible for long term investment?

2) Know value chain areas where players can create value?

3) Teritorry that may see steep rise in CAGR & Y-O-Y growth?

4) What geographic region would have better demand for product/services?

5) What opportunity emerging territory would offer to established and new entrants in Cancer Gene Therapy Market?

6) Risk side analysis connected with service providers?

7) How influencing factors driving the demand of Cancer Gene Therapyin next few years?

8) What is the impact analysis of various factors in the Global Cancer Gene Therapy Market growth?

9) What strategies of big players help them acquire share in mature market?

10) How Technology and Customer-Centric Innovation is bringing big Change in Cancer Gene Therapy Market?

Browse Trending Reports:

Cerebral Vasculitis Treatment Market
Additive Manufacturing With Metal Powders Market
Colistin Sulphate Market
Facioscapulohumeral Muscular Dystrophy Market
Converted Plastic Packaging Market
Local Anesthetics Market
Intelligent Milking Robot Market
Airborne Radars Market
Automotive Emission Test Equipment Market
Wire Cerclage Sternal Closure Systems Market
Collagen Supplements Market
Injectable Drug Delivery Market
Dental Radiology Equipment Market
Clinical Chemistry Analyzer Market
Single Tooth Implants And Dental Bridges Market
Weight Loss And Obesity Management Market
Nerve Repair Biomaterials Market
Medical Device Cleaning Market
Hypercalcemia Treatment Market
x Ray Inspection System Market
Industrial Lighting Market
Industrial Automation Market
Terminal Automation Market
Surgical Sealants Adhesives Market
Medical Gases Market
Ballistic Composites Market
Polyurethane Additives Market
Consumer Iam Market

 

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: [email protected]"

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Comments on “Cancer Gene Therapy Market Size, Share, Trends, Key Drivers, Demand and Opportunity Analysis”

Leave a Reply

Gravatar